Target intelligence / Profile preview

novel transcript, antisense to GALNTL6 (ENSG00000299213)

Target: ENSG00000299213
Molecular classification: Other, lncRNA, antisense RNA

Overview

"novel transcript, antisense to GALNTL6" (ENSG00000299213) is a computationally annotated, putative antisense long non-coding RNA transcript located in the genomic region opposite to the protein-coding gene GALNTL6. There is no experimental evidence for transcript function, disease association, druggability, or use as a biomarker. It is not recognized as a therapeutic target or a biologically relevant molecule for pharmaceutical intervention[1][4][7].

Mechanism of action

none

Biological functions

Unknown

Disease associations

Unknown

Beyond the preview

Go deeper on novel transcript, antisense to GALNTL6 (ENSG00000299213).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on novel transcript, antisense to GALNTL6 (ENSG00000299213).

Explore the full profile